We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+16.1%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$1.69B
AUM Growth
+$3.31M
Cap. Flow
-$44.3M
Cap. Flow %
-2.62%
Top 10 Hldgs %
77.31%
Holding
52
New
6
Increased
5
Reduced
4
Closed
15

Top Buys

Rank Stock Value
1
ITOS
iTeos Therapeutics
ITOS
+$86.1M
2
ZYME icon
Zymeworks
ZYME
+$68M
3
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$23.6M
4
ALKS icon
Alkermes
ALKS
+$14.9M
5
VRNA
Verona Pharma
VRNA
+$14.8M

Top Sells

Rank Stock Value
1
PRTA icon
Prothena Corp
PRTA
+$143M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$82.5M
3
ORIC icon
Oric Pharmaceuticals
ORIC
+$12.1M
4
BEAM icon
Beam Therapeutics
BEAM
+$10.3M
5
DNA icon
Ginkgo Bioworks
DNA
+$8.34M

Sector Composition

Rank Sector Weight
1 Healthcare 99.74%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCRX icon
26
Pacira BioSciences
PCRX
$1.01B
$10.9M 0.65%
+457,471
New +$11.5M
REPL icon
27
Replimune Group
REPL
$884M
$7.9M 0.47%
850,341
– –
MTSR
28
DELISTED
Metsera Inc
MTSR
$7.72M 0.46%
271,529
+221,529
+443% +$5.5M
ADAP
29
DELISTED
Adaptimmune Therapeutics
ADAP
$6.57M 0.39%
27,404,070
– –
DAWN
30
DELISTED
Day One Biopharmaceuticals
DAWN
$5.6M 0.33%
862,068
– –
HLVX
31
DELISTED
HilleVax
HLVX
$4.82M 0.29%
+2,420,243
New +$4.43M
ATRA icon
32
Atara Biotherapeutics
ATRA
$77M
$4.42M 0.26%
573,183
– –
WHWK
33
Whitehawk Therapeutics
WHWK
$189M
$2.04M 0.12%
1,091,417
-990,583
-48% -$1.72M
MGNX icon
34
MacroGenics
MGNX
$281M
$1.94M 0.11%
+1,602,717
New +$2.32M
QURE icon
35
CALL
uniQure
QURE
$2.77B
$1.88M 0.11%
135,000
– –
NUVB.WS
36
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$1.88M 0.11%
963,333
– –
SRZNW icon
37
Surrozen Inc Warrant
SRZNW
$596K 0.04%
66,665
– –
ALGS icon
38
Aligos Therapeutics
ALGS
$33.7M
– –
-88,569
Closed -$731K
BCYC
39
Bicycle Therapeutics
BCYC
$293M
– –
-910,000
Closed -$7.73M
BEAM icon
40
Beam Therapeutics
BEAM
$2.76B
– –
-526,685
Closed -$10.3M
DNA icon
41
Ginkgo Bioworks
DNA
$504M
– –
-1,462,328
Closed -$8.34M
ETON icon
42
CALL
Eton Pharmaceutcials
ETON
$1.13B
– –
-50,500
Closed -$655K
KROS icon
43
Keros Therapeutics
KROS
$212M
– –
-187,500
Closed -$1.91M
PRME icon
44
Prime Medicine
PRME
$564M
– –
-700,000
Closed -$1.39M
PRTA icon
45
Prothena Corp
PRTA
$451M
– –
-11,584,280
Closed -$143M
RLAY icon
46
Relay Therapeutics
RLAY
$4.25B
– –
-641,426
Closed -$1.68M
SLDB icon
47
Solid Biosciences
SLDB
$851M
– –
-744,450
Closed -$2.75M
SRPT icon
48
Sarepta Therapeutics
SRPT
$1.82B
– –
-1,292,386
Closed -$82.5M
TCRX icon
49
TScan Therapeutics
TCRX
$60.2M
– –
-662,833
Closed -$915K
VERV
50
DELISTED
Verve Therapeutics
VERV
– –
-1,250,000
Closed -$5.71M
1
2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $2.36B AUM 68.36% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return

EcoR1 Capital's Q2 2025 Portfolio in Review

As of Q2 2025, EcoR1 Capital held 52 positions worth $1.69B, up 0.2% from $1.69B the previous quarter. Its ten largest holdings account for 77% of the portfolio.

EcoR1 Capital's Q2 2025 filing shows 6 new, 5 increased, 4 reduced and 15 closed positions. Its largest new stake was iTeos Therapeutics: 10,688,978 shares worth $107M. The largest sale was Prothena Corp, an estimated $143M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • EcoR1 Capital's largest Q2 2025 buy was iTeos Therapeutics: 10,688,978 shares worth $107M.
  • EcoR1 Capital added most to Zymeworks in Q2 2025, an estimated $68M increase.
  • EcoR1 Capital's biggest Q2 2025 reduction was Oric Pharmaceuticals, cutting an estimated $12.1M.
  • EcoR1 Capital fully exited Prothena Corp in Q2 2025, selling an estimated $143M.
  • EcoR1 Capital's ten largest holdings make up 77% of its $1.69B portfolio in Q2 2025.
  • EcoR1 Capital opened 6 new positions and closed 15 in Q2 2025.
  • EcoR1 Capital's portfolio value rose 0.2% quarter-over-quarter to $1.69B.

Based on EcoR1 Capital's 13F filing for Q2 2025, filed 14 Aug 2025.